Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013

Applied Health Economics and Health Policy

Volumn 12, Issue 4, 2014, Pages 391-408

  Amin, Neha P ^a   Sher, David J ^b   Konski, Andre A ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDICARE; MEDLINE; PROSTATE CANCER; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; SENSITIVITY ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMATIC REVIEW; UNCERTAINTY; WATCHFUL WAITING; AGED; COST BENEFIT ANALYSIS; ECONOMICS; MALE; MORTALITY; PROBABILITY; PROCEDURES; PROSTATIC NEOPLASMS; STATISTICAL MODEL;

AGED; COST-BENEFIT ANALYSIS; HUMANS; MALE; MARKOV CHAINS; MODELS, ECONOMETRIC; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY;

EID: 84905017279     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0106-9     Document Type: Review

References (40)

1. IOM (Institute of Medicine). Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academics Press; 2009.
2. Ollendorf DA, Hayes J, McMahon P, Kuba M, Pearson SD. Management options for low-risk prostate cancer: a report on comparative effectiveness and value. http://www.icer-review.org/index.php/mgmtoptionlrpc.html. Boston: Institute for Clinical and Economic Review; 2009.
3. Siegel R, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.
4. Nguyen PL, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29(12):1517-24.
5. Dearnaley DP, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475-87. (Pubitemid 46805903)
6. Pollack A, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097-105. (Pubitemid 34787842)
7. Zietman AL, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - a randomized controlled trial. JAMA - J Am Med Assoc. 2005;294(10):1233-9. (Pubitemid 41352111)
8. Sheets NC, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307(15):1611-20.
9. Nutting CM, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48(3):649-56.
10. Zelefsky MJ, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124-9. (Pubitemid 351296130)
11. Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-94.
12. Hayes JH, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med. 2013;158(12):853-60.
13. Parthan A, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol. 2012;2:81.
14. Cooperberg MR, et al. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437-50.
15. Hummel S, et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess. 2003;7(33):iii, ix-x, 1-157.
16. Hummel SR, et al. A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clin Oncol (R Coll Radiol). 2012;24(10):e159-67.
17. Konski A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol. 2007;25(24):3603-8. (Pubitemid 47372597)
18. Konski A, et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66(2):408-15. (Pubitemid 44332736)
19. Sher DJ, et al. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol. 2014;37(3):215-21.
20. Yong JH, et al. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. Clin Oncol (R Coll Radiol). 2012;24(7):521-31.
21. Shah C, et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy. 2012;11(6):441-5.
22. Showalter TN, et al. Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis. Ann Oncol. 2012;23(3):701-6.
23. Quigley MM, Mate TP, Sylvester JE. Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses. Urol Oncol. 2009;27(5):473-82.
24. D'Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-74. (Pubitemid 28445094)
25. Kupelian PA, et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):904-12. (Pubitemid 34722635)
26. Kupelian PA, et al. Hypofractionated intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63(5):1463-8. (Pubitemid 41628043)
27. Morgan PB, et al. A matched pair comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy for prostate cancer: toxicity and outcomes. Int J Radiat Oncol Biol Phys. 2007:69(3):S319-S319.
28. Vora SA, et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68(4):1053-8. (Pubitemid 47048576)
29. Hodges JC, et al. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. J Oncol Pract. 2012;8(3 Suppl):e31s-7s.
30. Mohammed N, et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):204-12.
31. Swanson GP, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25(16):2225-9. (Pubitemid 46954647)
32. Thompson IM, Tangen CM, Klein EA. Is there a standard of care for pathologic stage T3 prostate cancer? J Clin Oncol. 2009;27(18):2898-9.
33. Thompson IM Jr, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296(19):2329-35.
34. Perrier L, et al. Cost of prostate image-guided radiation therapy: results of a randomized trial. Radiother Oncol. 2013;106(1):50-8.
35. Sher DJ, Punglia RS. Decision analysis and cost-effectiveness analysis for comparative effectiveness research-a primer. Semin Radiat Oncol. 2014;24(1):14-24.
36. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419-58. (Pubitemid 14196965)
37. Russell LB, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(14):1172-7. (Pubitemid 26329746)
38. Hayman JA, et al. A comparison of two methods for estimating the technical costs of external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2000;47(2):461-7. (Pubitemid 30236389)
39. Churchill DN, Lemon BC, Torrance GW. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Med Decis Making. 1984;4:489-500. (Pubitemid 15235561)
40. Winkelmayer WC, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22(5):417-30.